Primary Site >> Stomach Cancer
Gene >> ERBB2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. PMID: 2430175 Ref: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. PMID: 3003577 |
Ref: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. PMID: 3281095 |
Ref: A murine monoclonal antibody that recognizes an extracellular domain of the human c-erbB-2 protooncogene product. PMID: 2565325 Ref: Regulation of expression and transforming ability of the c-erbB-2 gene. PMID: 2577338 |
Ref: Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation. PMID: 1699198 Ref: DNA ploidy pattern and amplification of ERBB and ERBB2 genes in human gastric carcinomas. PMID: 1970690 Ref: Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. PMID: 1979253 Ref: Growth factors in progression of human esophageal and gastric carcinomas. PMID: 2098274 Ref: Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. PMID: 2253224 Ref: Gene amplification in gastric and esophageal adenocarcinomas. PMID: 2400999 |
Ref: Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. PMID: 1673870 Ref: c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. PMID: 1676988 Ref: Therapy of upper gastrointestinal tract cancers. PMID: 1743044 Ref: Biological significance of gene amplification in carcinogenesis. PMID: 1844251 Ref: Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells. PMID: 1849125 Ref: [Cancer metastasis and recurrence from the standpoint of amplification and expression of oncogenes in human malignant tumors]. PMID: 1944161 Ref: [Molecular diagnosis of gastric cancer]. PMID: 1987903 Ref: Extraction of DNA from paraffin blocks for Southern blot analysis. PMID: 1989465 Ref: [Oncogene and patient prognosis]. PMID: 2053766 |
Ref: [New prognostic factors in human gastric carcinomas]. PMID: 1346086 Ref: Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. PMID: 1352299 Ref: Tumor-specific methylation patterns of erbB2 (HER2/neu) sequences in gastro-intestinal cancer. PMID: 1352439 Ref: Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. PMID: 1352878 Ref: c-erbB-2 expression in primary gastric carcinomas and their metastases. PMID: 1353880 Ref: [Expression of soluble c-erbB-2 protein in serum of gastric cancer patients: preliminary report]. PMID: 1355258 Ref: Clinical significance of erbB-2 (HER-2/neu) protein. PMID: 1358410 Ref: Specific detection of c-erbB-2 mRNA expression in gastric cancers by the polymerase chain reaction following reverse transcription. PMID: 1379062 Ref: Amplification and overexpression of the c-erbB-2 protooncogene in human gastric cancer. PMID: 1577221 |
Ref: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. PMID: 7688814 Ref: Immunohistochemical detection of p53 protein, c-erbB-2 protein, epidermal growth factor receptor protein and proliferating cell nuclear antigen in gastric carcinoma. PMID: 7911025 Ref: An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? PMID: 8093216 Ref: Amplified genes in cancer in upper digestive tract. PMID: 8095412 Ref: Construction of immunoradiometric assay for circulating c-erbB-2 protooncogene product in advanced breast cancer patients. PMID: 8096502 Ref: [Correlation of DNA ploidy, c-erbB-2 protein tissue status, level of PCNA expression and clinical outcome in gastric carcinomas]. PMID: 8098198 Ref: Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. PMID: 8099338 Ref: neu mutations and loss of normal allele in schwannomas induced by N-ethyl-N-nitrosourea in rats. PMID: 8330300 Ref: Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. PMID: 8397058 Ref: DNA amplification in human gastric carcinomas. PMID: 8453595 |
Ref: Alteration of immunoreactivity by hydrated autoclaving, microwave treatment, and simple heating of paraffin-embedded tissue sections. PMID: 7516673 Ref: Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP. PMID: 7525029 Ref: [Metastasis-related genes]. PMID: 7526801 Ref: Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. PMID: 7907612 Ref: Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma. PMID: 7907854 Ref: [Molecular biology and immunohistochemical studies of Her2/neu oncogene in stomach cancer]. PMID: 7912666 Ref: Expression of p185erbB2 and p21ras in carcinoma, dysplasia, and intestinal metaplasia of the stomach: an immunohistochemical and in situ hybridization study. PMID: 7914379 Ref: Effect of hepatocyte growth factor on the expression of E- and P-cadherin in gastric carcinoma cell lines. PMID: 7952499 Ref: The prognostic significance of c-erbB-2 and p53 protein expressions in gastric carcinoma--a multivariate analysis of prognostic factors. PMID: 7993593 |
Ref: Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. PMID: 7734322 Ref: [Correlation of DNA ploidy, c-erB-2 protein tissue status, level of PCNA expression and clinical outcome in gastric carcinomas]. PMID: 7753016 Ref: Gastric carcinoma: recent issues in prognostic factors. PMID: 7775839 Ref: [Rearrangement of the c-erbB2 oncogene--analysis of the gastrocolic carcinoma]. PMID: 7884965 Ref: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. PMID: 7889468 Ref: [Multiple gene alterations involved in the processor of human gastric carcinogenesis]. PMID: 8697090 Ref: [Expression of ras and erbB2 in benign and malignant lesions of the stomach]. PMID: 8697969 Ref: Immunoselective cell growth inhibition by antibody-adriamycin conjugates targeting c-erbB-2 product on human cancer cells. PMID: 8845823 |
Ref: Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. PMID: 8643220 Ref: In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. PMID: 8645580 Ref: [Genetic alterations in stomach cancer]. PMID: 8692139 Ref: Expression of bcl-2 by breast cancer: a possible diagnostic application. PMID: 8729986 Ref: [Activation of proto-oncogenes induced by MNNG on primary culture of human gastric epithelium and immortalized human gastric epithelial cell line]. PMID: 8732101 Ref: Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. PMID: 8806677 Ref: Fibropapule multiplex of the nose: a variant of Cowden's disease? PMID: 8864382 Ref: [Multistep stomach carcinogenesis]. PMID: 8920675 Ref: Hereditary onset of multiple seborrheic keratoses: a variant of Leser Trelat sign? PMID: 8935630 Ref: [Correlation of multiple gene changes with malignant phenotype of human gastric carcinoma]. PMID: 9275549 Ref: [Multiple genetic expression abnormalities in gastric cancer]. PMID: 9387254 Ref: [Clinical significance of c-erbB2 oncoprotein expression in stomach carcinoma]. PMID: 9387327 Ref: Growth inhibition of gastric cancer cell lines by the tyrphostin RG13022 and its effects on intracellular signalling. PMID: 21544401 Ref: Histogenesis of the gastric differentiated adenocarcinoma-expression of oncogene protein products and mucin histochemistry in minute gastric cancer. PMID: 21594479 |
Ref: c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma. PMID: 9058162 Ref: Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. PMID: 9088037 Ref: Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. PMID: 9136822 Ref: Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. PMID: 9143415 Ref: Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. PMID: 9164544 Ref: Low epithelial cell proliferation and absence of oncoprotein expression in juvenile polyposis of the stomach, with or without tumors. PMID: 9260812 Ref: Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. PMID: 9284825 Ref: c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. PMID: 9315057 Ref: Multiple simultaneous gastric carcinomas. PMID: 9413949 Ref: Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. PMID: 9428926 Ref: Capsaicin can alter the expression of tumor forming-related genes which might be followed by induction of apoptosis of a Korean stomach cancer cell line, SNU-1. PMID: 9461043 Ref: [Immunohistochemical study of p53, c-erbB-2 and nm23 proteins in human gastric cancer]. PMID: 10920922 Ref: A Humanized Anti-c-erbB-2 Monoclonal Antibody for the Treatment of Breast Cancer. PMID: 11091613 |
Ref: Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization. PMID: 9520947 Ref: Prognostic significance of c-erbB-2 gene expression in the poorly differentiated type of adenocarcinoma of the stomach. PMID: 9544434 Ref: Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages. PMID: 9570245 Ref: Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. PMID: 9703936 Ref: Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. PMID: 9732228 Ref: Multiple early gastric stump carcinomas after gastrectomy for peptic ulcer. PMID: 9732951 Ref: Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. PMID: 9754653 Ref: Prognostic factors in gastric cancer. PMID: 9758367 Ref: Cathepsin D expression in skin metastasis of breast cancer. PMID: 9765021 Ref: Expression of cadherin-catenin cell adhesion molecules, phosphorylated tyrosine residues and growth factor receptor-tyrosine kinases in gastric cancers. PMID: 9765619 Ref: HER-2/Neu expression as a progression marker in pancreatic intraepithelial neoplasia. PMID: 9798411 Ref: Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. PMID: 9824203 Ref: [New molecular prognostic markers in gastric carcinoma]. PMID: 9838902 Ref: Reproducible and sensitive determination of charged oligosaccharides from haptoglobin by PNGase F digestion and HPAEC/PAD analysis: glycan composition varies with disease. PMID: 9881748 Ref: [MMP-2 expression (type IV collagenase) in gastric cancer]. PMID: 10347682 |
Ref: Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer. PMID: 9892105 Ref: Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. PMID: 9927058 Ref: Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. PMID: 9973227 Ref: Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67. PMID: 10393360 Ref: The relationship between c-erbB-2 oncogene expression and clinicopathological factors in gastric cancer. PMID: 10446693 Ref: Inhibition by rat C-erbB-2/neu antisense oligonucleotide of gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. PMID: 10521805 Ref: Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. PMID: 10535875 Ref: Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types. PMID: 10619912 Ref: [Molecular biology in gastric cancer]. PMID: 10635296 Ref: [Reversion of the malignant phenotype of gastric cancer by c-erbB-2 specific ribozyme]. PMID: 11601058 Ref: [Gene detection and localization by FISH with short DNA fragment cloned in plasmid]. PMID: 11776569 Ref: [Helicobacter pylori infection and expression of PCNA, p53, c-erbB-2 in carcinoma and precancerours lesions of the stomach]. PMID: 11776853 Ref: Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer. PMID: 11819416 |
Ref: Expression of cell cycle regulators and growth factor/receptor systems in gastric carcinoma in young adults: association with Helicobacter pylori infection. PMID: 10639599 Ref: Flow cytometric DNA ploidy, p53, PCNA, and c-erbB-2 protein expressions as predictors of survival in surgically resected gastric cancer patients. PMID: 10679740 Ref: Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue. PMID: 10754464 Ref: Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. PMID: 10809364 Ref: c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. PMID: 10829039 Ref: Development of a cancer vaccine: peptides, proteins, and DNA. PMID: 10950153 Ref: C-erbB-2 oncoprotein content in gastric cancer and in adjacent mucosa. PMID: 11012099 Ref: Molecular characteristics of eight gastric cancer cell lines established in Japan. PMID: 11107048 Ref: Tyrosine kinases and gastric cancer. PMID: 11114748 Ref: The use of molecular biology in diagnosis and prognosis of gastric cancer. PMID: 11525306 |
Ref: Genetic and epigenetic changes in stomach cancer. PMID: 11243597 Ref: Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. PMID: 11360194 Ref: Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. PMID: 11396210 Ref: Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene. PMID: 11399867 Ref: Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. PMID: 11489825 Ref: Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. PMID: 11521716 Ref: Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma. PMID: 11680933 Ref: Risk factors for lymph node metastasis of submucosal invasive differentiated type gastric carcinoma: clinical significance of histological heterogeneity. PMID: 11686475 Ref: Total synthesis and biological evaluation of the nakijiquinones. PMID: 11716712 Ref: Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme. PMID: 11773973 Ref: C-erbB-2 oncoprotein in gastric carcinoma: correlation with clinical stage and prognosis. PMID: 11820720 |
Ref: Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. PMID: 11796015 Ref: Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. PMID: 11809769 Ref: p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. PMID: 11837710 Ref: Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. PMID: 11857411 Ref: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. PMID: 11948459 Ref: Targets of gene amplification and overexpression at 17q in gastric cancer. PMID: 11980659 Ref: C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms. PMID: 12373150 Ref: Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. PMID: 12384543 Ref: Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. PMID: 12429626 Ref: c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. PMID: 12490974 Ref: Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. PMID: 12530043 Ref: The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. PMID: 12579211 Ref: [Genetics and environmental factors in gastric carcinogenesis]. PMID: 12870086 |
Ref: Clinicopathologic characteristics and prognoses of gastric cancer in patients with a positive familial history of cancer. PMID: 12488704 Ref: Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis. PMID: 12548420 Ref: Activation of ErbB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas. PMID: 12618754 Ref: Detection of bone marrow micrometastasis in gastric cancer patients by immunomagnetic separation. PMID: 12620913 Ref: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. PMID: 12679307 Ref: Tumour suppressor gene expression correlates with gastric cancer prognosis. PMID: 12692839 Ref: Sustained delivery of Her-2/neu antibody by TCPL delivery device using adult male rats as a model. PMID: 12724914 Ref: MGC9753 gene, located within PPP1R1B-STARD3-ERBB2-GRB7 amplicon on human chromosome 17q12, encodes the seven-transmembrane receptor with extracellular six-cystein domain. PMID: 12739007 Ref: Helicobacter pylori infection affects the expression of PCNA, p53, c-erbB-2 and Bcl-2 in the human gastric mucosa. PMID: 12760717 Ref: Molecular mechanisms of carcinogenesis in gastric cancer. PMID: 12790321 Ref: Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. PMID: 12800215 Ref: Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. PMID: 12810831 Ref: A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. PMID: 14520697 Ref: HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples. PMID: 14532980 Ref: Epidermal growth factor receptor and c-erbB-2 contents in unresectable (UICC R1 or R2) gastric cancer. PMID: 14535591 Ref: [Generation of HER2 specific, HLA-A24 restricted CTLs derived from gastric cancer patients]. PMID: 14619524 Ref: [Effect of learning about the human genome on the development of pathology]. PMID: 14974156 Ref: The Prognostic Significance of the Overexpression of HER-2/ neu in Korean Gastric Carcinomas and the In Vitro Effects of Anti-HER-2/neu Antibody on Cell Growth in the Gastric Carcinoma Cell Lines. PMID: 26680923 |
Ref: Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. PMID: 14618618 Ref: Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. PMID: 14719064 Ref: Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. PMID: 14991576 Ref: Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon. PMID: 15010812 Ref: Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with epstein-barr virus-negative carcinoma. PMID: 15014022 Ref: Monoclonal antibodies as effective therapeutic agents for solid tumors. PMID: 15298722 Ref: Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. PMID: 15363548 Ref: A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. PMID: 15517369 Ref: Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. PMID: 15640503 Ref: Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance. PMID: 15646832 Ref: Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. PMID: 20368841 |
Ref: CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors. PMID: 15614528 Ref: Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells. PMID: 15649431 Ref: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. PMID: 15668283 Ref: Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. PMID: 15870832 Ref: Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. PMID: 15928192 Ref: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. PMID: 16077916 Ref: [Monoclonal antibody against G3BP: preparation, characterization and its application in analysis of human tumors]. PMID: 16091175 Ref: The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. PMID: 16121348 Ref: Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach. PMID: 16254038 Ref: Epithelial-mesenchymal transition in gastric cancer (Review). PMID: 16273224 Ref: Nonrandom chromosomal numerical abnormality as a new molecular cytogenetic tumor marker--a retrospective study of 60 gastric cancer cases. PMID: 16296333 Ref: ERBB2 kinase domain mutation in a gastric cancer metastasis. PMID: 16309427 Ref: [Clinical and molecular features of cardial gastric cancer associated to Epstein Barr virus]. PMID: 16341380 Ref: Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. PMID: 16457151 |
Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. PMID: 16328035 Ref: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. PMID: 16397024 Ref: A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2 PMID: 16406575 Ref: Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. PMID: 16490596 Ref: Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. PMID: 16492916 Ref: [Association of HER-2/neu expression with prognosis of gastric cancer]. PMID: 16546744 Ref: Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. PMID: 16557436 Ref: Mediterranean diet, olive oil and cancer. PMID: 16632435 Ref: Increased epithelial cadherin expression among Japanese intestinal-type gastric cancers compared with specimens from American patients of European descent. PMID: 16676859 Ref: Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. PMID: 16718853 Ref: HER-2/neu amplification is an independent prognostic factor in gastric cancer. PMID: 16868827 Ref: Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. PMID: 16949920 Ref: Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. PMID: 17047397 Ref: Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. PMID: 17088902 |
Ref: Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. PMID: 17031648 Ref: Collision carcinoma of the residual cervical esophagus 27 years after esophageal cancer surgery. PMID: 17348434 Ref: Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. PMID: 19034345 |
Ref: Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. PMID: 17628829 Ref: The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. PMID: 17851763 Ref: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. PMID: 18097546 Ref: Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies. PMID: 18224443 Ref: Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. PMID: 18258606 Ref: [Future directions of anticancer drug development in Japan]. PMID: 18281781 Ref: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. PMID: 18381441 Ref: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. PMID: 18422971 Ref: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. PMID: 18441328 Ref: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. PMID: 18483367 Ref: Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. PMID: 18505086 Ref: Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. PMID: 18506690 Ref: Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. PMID: 18544998 Ref: Does hyaluronic acid stimulate tumor growth after endoscopic mucosal resection? PMID: 18637056 Ref: The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. PMID: 18774637 Ref: Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. PMID: 18798223 Ref: Molecular targets and biological modifiers in gastric cancer. PMID: 19013893 Ref: High expression of HER3 is associated with a decreased survival in gastric cancer. PMID: 19047113 Ref: Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. PMID: 19061514 |
Ref: Comparative analysis of protein expressions in primary and metastatic gastric carcinomas. PMID: 18835621 Ref: Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. PMID: 19082474 Ref: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. PMID: 19156142 Ref: Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. PMID: 19337752 Ref: Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. PMID: 19412098 Ref: Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. PMID: 19448398 Ref: Novel investigational drugs for gastric cancer. PMID: 19466878 Ref: ERBB2 suppression decreases cell growth via apoptosis in gastrointestinal adenocarcinomas. PMID: 19628076 Ref: Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. PMID: 19636613 Ref: A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. PMID: 19654310 Ref: [Differential expression of immunohistochemical markers between cardiac carcinoma and carcinoma in antrum of stomach and correlation thereof with clinicopathological factors]. PMID: 19671307 Ref: Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. PMID: 19734198 Ref: Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue. PMID: 19783961 Ref: Trastuzumab for gastric cancer. PMID: 19916733 Ref: Study on the different expression of molecular markers between cardiac cancer and distal gastric cancer and their correlations with clinicopathological features. PMID: 19923826 Ref: Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach. PMID: 20430735 Ref: HER 2/neu protein expression in gastric cancer is associated with poor survival. PMID: 21475925 Ref: Peripheral position of CCND1 and HER-2/neu oncogenes within chromosome territories in esophageal and gastric cancers non-related to amplification and overexpression. PMID: 21637674 |
Ref: Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein. PMID: 19951902 Ref: Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer. PMID: 19956838 Ref: [Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma]. PMID: 20038314 Ref: Circulating tumour-derived microvesicles in plasma of gastric cancer patients. PMID: 20043223 Ref: Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma. PMID: 20082479 Ref: A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. PMID: 20130877 Ref: Advanced gastric cancer--slow but steady progress. PMID: 20176443 Ref: Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. PMID: 20179222 Ref: Targeted HER2 treatment in advanced gastric cancer. PMID: 20185938 Ref: Genome-wide gene copy number and expression analysis of primary gastric tumors and gastric cancer cell lines. PMID: 20187983 Ref: HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. PMID: 20208134 Ref: Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. PMID: 20331976 Ref: The role of HER2 in cancer therapy and targeted drug delivery. PMID: 20385184 Ref: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. PMID: 20410336 Ref: Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. PMID: 20424000 Ref: [HER2 testing and targeted therapy in advanced gastric cancer]. PMID: 20431310 Ref: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. PMID: 20443098 Ref: HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. PMID: 20460098 Ref: Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. PMID: 20496540 Ref: Down-regulation of human epidermal growth factor receptor 2/neu oncogene by corosolic acid induces cell cycle arrest and apoptosis in NCI-N87 human gastric cancer cells. PMID: 20522955 Ref: The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines. PMID: 20590442 Ref: [Expression of a chimeric gene containing poly-arginine as the protein transduction domain and its killing activity against HER2 positive gastric cancer SGC-7901 cells]. PMID: 20619096 Ref: Cytogenetic characterization and evaluation of c-MYC gene amplification in PG100, a new Brazilian gastric cancer cell line. PMID: 20658094 Ref: HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. PMID: 20665045 Ref: A study of HER2 gene amplification and protein expression in gastric cancer. PMID: 20696687 Ref: Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes. PMID: 20700725 Ref: [Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer]. PMID: 20716873 Ref: [Diagnosis and treatment of gastric cancer]. PMID: 20721843 Ref: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. PMID: 20728210 Ref: Induction of apoptosis by 5,7-dihydroxy-8-nitrochrysin in breast cancer cells: the role of reactive oxygen species and Akt. PMID: 20878083 Ref: Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. PMID: 21058730 Ref: Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. PMID: 21129604 Ref: [HER2 and gastric cancer: a novel therapeutic target for trastuzumab]. PMID: 21134821 Ref: Recent advances in chemotherapy for advanced gastric cancer. PMID: 21160659 Ref: [Pathology background of targeted therapy; quality control in pathology]. PMID: 21163765 Ref: Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. PMID: 21188213 Ref: Expression of HER2 in colorectal cancer does not correlate with prognosis. PMID: 21206005 Ref: [HER2 expression in gastric cancer in Peru]. PMID: 21263759 Ref: Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer. PMID: 22966343 |
Ref: Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. PMID: 20975737 Ref: Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. PMID: 21097718 Ref: Feasibility of tailored, selective and effective anticancer chemotherapy by direct injection of docetaxel-loaded immunoliposomes into Her2/neu positive gastric tumor xenografts. PMID: 21109923 Ref: Proteomics-based identification of a group of apoptosis-related proteins and biomarkers in gastric cancer. PMID: 21165559 Ref: HER2 testing in gastric cancer. PMID: 21169738 Ref: MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. PMID: 21220473 Ref: ADAM 10 is associated with gastric cancer progression and prognosis of patients. PMID: 21259244 Ref: Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. PMID: 21267790 Ref: [Recent results of research on cancer of the colon, gastric cancer, sarcoma and bronchial carcinoma]. PMID: 21271476 Ref: Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer. PMID: 21306821 Ref: HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). PMID: 21323962 Ref: Interaction between adipose tissue stromal cells and gastric cancer cells in vitro. PMID: 21384185 Ref: Low frequency of HER2 amplification and overexpression in early onset gastric cancer. PMID: 21394646 Ref: New targeted therapies for gastric cancer. PMID: 21406037 Ref: Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. PMID: 21415234 Ref: Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. PMID: 21421462 Ref: Incorporation of targeted agents in the management of patients with advanced gastric cancer. PMID: 21428884 Ref: Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. PMID: 21458915 Ref: Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. PMID: 21468783 Ref: Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. PMID: 21472111 Ref: Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. PMID: 21487037 Ref: How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? PMID: 21505336 Ref: Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. PMID: 21516080 Ref: Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. PMID: 21532492 Ref: New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. PMID: 21552412 Ref: [Standardization of evaluation for target molecule in cancer therapy]. PMID: 21566428 Ref: Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. PMID: 21567388 Ref: [HER2 and gastric cancer. Recommendations for clinical practice in 2011]. PMID: 21601111 Ref: Gastric metastasis of breast cancer: a single centre retrospective study. PMID: 21616731 Ref: Where and by whom should gastric cancer HER2/neu status be assessed?: lessons from breast cancer. PMID: 21631260 Ref: Esophagogastric cancer: integration of targeted therapies into systemic chemotherapy. PMID: 21651462 Ref: Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas. PMID: 21670724 Ref: HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test. PMID: 21673877 Ref: Correlation between genomic alterations assessed by array comparative genomic hybridization, prognostically informative histologic subtype, stage, and patient survival in gastric cancer. PMID: 21676433 Ref: Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization. PMID: 21689422 Ref: Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. PMID: 21700765 Ref: Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. PMID: 21709195 Ref: Prognostic significance of HER2/neu expression in gastric cancer. PMID: 21739203 Ref: [Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma]. PMID: 21756821 Ref: [Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma]. PMID: 21756822 Ref: Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. PMID: 21757431 Ref: The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells. PMID: 21767874 Ref: Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. PMID: 21771023 Ref: [Relation of HER2 status and prognosis in gastric cancer patients]. PMID: 21772089 Ref: HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. PMID: 21791637 Ref: The role of neuregulin4 and HER4 in gastrointestinal malignant lymphoma. PMID: 21805036 Ref: Quality assessment of HER2 testing by monitoring of positivity rates. PMID: 21809092 Ref: Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. PMID: 21811258 Ref: Targeted therapies for gastric cancer: current status. PMID: 21812503 Ref: HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. PMID: 21865130 Ref: Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. PMID: 21865135 Ref: [Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. PMID: 21868346 Ref: Systemic therapy for advanced gastric cancer: a clinical practice guideline. PMID: 21874111 Ref: Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. PMID: 21880153 Ref: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. PMID: 21925125 Ref: Co-expression of erythropoietin receptor with human epidermal growth factor 2 may counteract trastuzumab inhibition in gastric cancer. PMID: 21944379 Ref: Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? PMID: 21955806 Ref: Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. PMID: 21959871 Ref: Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. PMID: 21967344 Ref: Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). PMID: 21985855 Ref: An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells. PMID: 21997136 Ref: HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. PMID: 22089490 Ref: Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. PMID: 22092393 Ref: Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. PMID: 22092394 Ref: Case report and literature review: Metastatic lobular carcinoma of the breast an unusual presentation. PMID: 22096760 Ref: Molecular pathology of gastric carcinoma. PMID: 22104201 Ref: HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain. PMID: 22131990 Ref: [Predictive diagnosis of HER2 in gastric adenocarcinoma]. PMID: 22145214 Ref: [Guidelines for HER2 detection in gastric cancer]. PMID: 22169647 Ref: [Standardization of HER2 testing in gastric cancer]. PMID: 22177257 Ref: Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis. PMID: 22229170 Ref: The Prognostic Significance of Her2-Neu Over expression in Gastric Carcinomas. PMID: 26322194 |
Ref: The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer. PMID: 21479551 Ref: Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. PMID: 21547408 Ref: Reversible posterior leukoencephalopathy syndrome and trastuzumab. PMID: 21633924 Ref: Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype. PMID: 21743497 Ref: HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. PMID: 21745161 Ref: Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review. PMID: 21780108 Ref: Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? PMID: 21855114 Ref: Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. PMID: 21927816 Ref: Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland. PMID: 22012551 Ref: Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. PMID: 22050138 Ref: HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. PMID: 22064554 Ref: HER2 status in unusual histological variants of gastric adenocarcinomas. PMID: 22067088 Ref: Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. PMID: 22116464 Ref: Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. PMID: 22135232 Ref: Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. PMID: 22179434 Ref: Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence. PMID: 22213294 Ref: Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma. PMID: 22213295 Ref: HER2 testing in gastric cancer: a practical approach. PMID: 22222640 Ref: Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract. PMID: 22229849 Ref: MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. PMID: 22238368 Ref: Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. PMID: 22253521 Ref: Her-2/neu assessment for gastric carcinoma: validation of scoring system. PMID: 22260838 Ref: Biomarkers for antitumor activity of bevacizumab in gastric cancer models. PMID: 22273502 Ref: HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity. PMID: 22281973 Ref: Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. PMID: 22314190 Ref: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. PMID: 22315472 Ref: Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. PMID: 22325735 Ref: [A case of hepatoid adenocarcinoma of the stomach]. PMID: 22333645 Ref: Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. PMID: 22371427 Ref: Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. PMID: 22374460 Ref: Management of advanced gastric cancer. PMID: 22375525 Ref: Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients. PMID: 22379747 Ref: HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. PMID: 22431535 Ref: Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. PMID: 22437741 Ref: Current status of targeted therapies in advanced gastric cancer. PMID: 22443228 Ref: Improving treatment of HER2-positive cancers: opportunities and challenges. PMID: 22461643 Ref: Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells. PMID: 22465967 Ref: HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. PMID: 22481979 Ref: The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. PMID: 22493400 Ref: Dendritic cell therapy in advanced gastric cancer: a promising new hope? PMID: 22521560 Ref: Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression. PMID: 22534547 Ref: Tumor size predicts survival in mucinous gastric carcinoma. PMID: 22535583 Ref: Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. PMID: 22542611 Ref: Targeted therapy for gastric cancer. PMID: 22552927 Ref: HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. PMID: 22569536 Ref: The correlations between the expression of FGFR4 protein and clinicopathological parameters as well as prognosis of gastric cancer patients. PMID: 22585711 Ref: The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. PMID: 22591714 Ref: Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. PMID: 22614071 Ref: PTEN deletion is rare but often homogeneous in gastric cancer. PMID: 22639407 Ref: Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis. PMID: 22646266 Ref: Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. PMID: 22654433 Ref: Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. PMID: 22689179 Ref: Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization. PMID: 22691185 Ref: Novel targeted agents for gastric cancer. PMID: 22709792 Ref: A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2. PMID: 22732416 Ref: Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. PMID: 22751336 Ref: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. PMID: 22751462 Ref: Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2. PMID: 22752927 Ref: HER2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study. PMID: 22760626 Ref: HER2 as a therapeutic target in the gastric cancer: is it sufficient? PMID: 22763895 Ref: Immunohistochemical biomarkers in gastric cancer research and management. PMID: 22778942 Ref: HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer. PMID: 22796163 Ref: A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). PMID: 22824079 Ref: Comparison of HER2 immunohistochemical results using a monoclonal antibody (SV2-61gamma) and a polyclonal antibody (for Dako HercepTest) in advanced gastric cancer. PMID: 22827758 Ref: Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. PMID: 22846108 Ref: Early HER2 dysregulation in gastric and oesophageal carcinogenesis. PMID: 22882541 Ref: Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. PMID: 22899293 Ref: Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. PMID: 22929309 Ref: Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine. PMID: 22943015 Ref: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. PMID: 22977193 Ref: Targetting esophageal and gastric cancers with monoclonal antibodies. PMID: 22978338 Ref: Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy. PMID: 22980219 Ref: [Determination of the possibilities of targeted therapy for gastric cancer]. PMID: 22997951 Ref: Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. PMID: 23007148 Ref: Apoptosis signal-regulating kinase-1 inhibitor as a potent therapeutic drug for the treatment of gastric cancer. PMID: 23110662 Ref: Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). PMID: 23121603 Ref: Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. PMID: 23180947 Ref: [Genetic and epigenetic alterations in gastric carcinogenesis]. PMID: 23198549 Ref: [Recent advance of chemotherapy in gastric cancer]. PMID: 23198562 Ref: [Molecular targeting agents for advanced or recurrent gastric cancer patients]. PMID: 23198568 Ref: [Molecular target for Her2 positive gastric cancer]. PMID: 23221049 Ref: [A case of HER2-positive and AFP-producing gastric cancer successfully treated by trastuzumab/docetaxel/S-1 combination therapy]. PMID: 23235175 Ref: [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy]. PMID: 23235178 Ref: Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. PMID: 23236232 Ref: Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. PMID: 23249720 Ref: [A case of unresectable HER2-positive advanced gastric cancer successfully treated by combination therapy with trastuzumab and paclitaxel]. PMID: 23268070 Ref: [Development of antibody drugs targeting against HER2 for cancer therapy]. PMID: 23289141 Ref: Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. PMID: 23303024 Ref: [The search for protein overexpression and HER2 gene amplification in gastric cancer by immunohistochemistry and in situ hybridization: experience of the CHU Hassan II of Fez]. PMID: 23397021 Ref: Trastuzumab (Herceptin) Therapy and ERBB2 (HER2) Genotype PMID: 28520362 |
Ref: HER2 expression and its clinicopathological features in resectable gastric cancer. PMID: 22410801 Ref: Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. PMID: 22676551 Ref: Targeted therapy for gastric cancer--current status. PMID: 22711713 Ref: Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. PMID: 22797858 Ref: Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer. PMID: 22820657 Ref: HER2 status of gastric carcinoma and corresponding lymph node metastasis. PMID: 22907801 Ref: Are biopsy specimens predictive of HER2 status in gastric cancer patients? PMID: 22918687 Ref: Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models. PMID: 22973964 Ref: Advanced HER2-positive gastric cancer: current and future targeted therapies. PMID: 23021388 Ref: In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. PMID: 23084583 Ref: Current questions for the treatment of advanced gastric cancer. PMID: 23102520 Ref: Over-expression of HER2 in Indian patients with gastric cancer. PMID: 23111642 Ref: A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. PMID: 23131390 Ref: Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. PMID: 23139264 Ref: Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. PMID: 23144237 Ref: Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. PMID: 23146959 Ref: Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. PMID: 23187882 Ref: Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. PMID: 23196062 Ref: Image cytometric HER2 in gastric carcinoma: is a new algorithm needed? PMID: 23197004 Ref: HER3 overexpression and survival in solid tumors: a meta-analysis. PMID: 23221996 Ref: Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. PMID: 23233651 Ref: Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. PMID: 23238628 Ref: A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. PMID: 23274580 Ref: Impact of genetic targets on cancer therapy in esophagogastric cancer. PMID: 23288635 Ref: The evolving role of HER2 evaluation for diagnosis and clinical decision making for breast and gastric adenocarcinoma. PMID: 23293935 Ref: [HER2 testing for advanced recurrent gastric cancer in a general hospital]. PMID: 23306919 Ref: Status of tissue expression and serum levels of HER2 in gastric cancer patients in Japan. PMID: 23321006 Ref: Suitability of endoscopic submucosal dissection for treatment of submucosal gastric cancers. PMID: 23334982 Ref: HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. PMID: 23348899 Ref: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal. PMID: 23371465 Ref: A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PMID: 23372746 Ref: Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. PMID: 23395886 Ref: Identification of ROS1 rearrangement in gastric adenocarcinoma. PMID: 23400546 Ref: [Two cases of unresectable advanced gastric cancer treated with S-1, CDDP and trastuzumab]. PMID: 23411963 Ref: The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. PMID: 23420289 Ref: Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. PMID: 23445612 Ref: Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. PMID: 23450234 Ref: HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH. PMID: 23455182 Ref: Amplification of the human epidermal growth factor receptor 2 gene in differentiated thyroid cancer correlates with telomere shortening. PMID: 23467725 Ref: Heterogeneous target protein expression in synchronous multiple gastric carcinomas. PMID: 23469621 Ref: Immunohistochemical analysis of invasive micropapillary carcinoma pattern in four cases of gastric cancer. PMID: 23471758 Ref: Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab. PMID: 23474221 Ref: Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers. PMID: 23489260 Ref: Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. PMID: 23524864 Ref: Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab. PMID: 23534710 Ref: [Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer]. PMID: 23536352 Ref: Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. PMID: 23536719 Ref: The expression of Egfl7 in human normal tissues and epithelial tumors. PMID: 23558933 Ref: HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype. PMID: 23564704 Ref: A review on biomarkers for prediction of treatment outcome in gastric cancer. PMID: 23564763 Ref: [Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure]. PMID: 23575230 Ref: Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. PMID: 23578997 Ref: Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. PMID: 23599643 Ref: Trastuzumab emtansine: first global approval. PMID: 23620199 Ref: Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. PMID: 23630281 Ref: Catecholamine-Induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. PMID: 23630346 Ref: HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. PMID: 23656792 Ref: Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PMID: 23658725 Ref: Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. PMID: 23667204 Ref: 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer. PMID: 23670095 Ref: Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. PMID: 23745034 Ref: Clinical significance of vimentin expression and Her-2 status in patients with gastric carcinoma. PMID: 23751022 Ref: Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. PMID: 23765245 Ref: Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model. PMID: 23783223 Ref: HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. PMID: 23788757 Ref: Epstein-Barr virus-encoded small non-coding RNAs induce cancer cell chemoresistance and migration. PMID: 23791019 Ref: HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. PMID: 23800891 Ref: Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. PMID: 23819947 Ref: Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. PMID: 23822993 Ref: Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. PMID: 23843458 Ref: Analysis of the polymorphisms EGFR-r521K and ERBB2-I655V in Mexican patients with gastric cancer and premalignant gastric lesions. PMID: 23844533 Ref: [A case of AFP-producing gastric cancer with peritoneal metastasis treated effectively with chemotherapy, mainly using S-1 and trastuzumab]. PMID: 23848022 Ref: A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5). PMID: 23852648 Ref: [Comparison of HER2 immunohistochemical results for advanced gastric cancer obtained on using 3 different antibodies]. PMID: 23863652 Ref: [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. PMID: 23863740 Ref: Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. PMID: 23871709 Ref: Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas. PMID: 23874879 Ref: [Clinical significance of human epidermal growth factor receptor family molecules expression in gastric cancer]. PMID: 23888453 Ref: HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest). PMID: 23910175 Ref: Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. PMID: 23911227 Ref: Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110alpha inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. PMID: 23918797 Ref: Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. PMID: 23930209 Ref: Brain metastasis as the first symptom of gastric cancer--case report and literature review. PMID: 23945118 Ref: HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. PMID: 23946770 Ref: [Therapeutic strategy for recurrent gastric cancer and efforts aimed at finding a cure]. PMID: 23986038 Ref: Clinical and molecular characterization of HER2 amplified-pancreatic cancer. PMID: 24004612 Ref: Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer. PMID: 24005419 Ref: Helicobacter pylori: gastric cancer and extragastric malignancies - clinical aspects. PMID: 24011244 Ref: CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. PMID: 24026662 Ref: Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. PMID: 24035511 Ref: Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. PMID: 24057416 Ref: Gastric cancer-molecular and clinical dimensions. PMID: 24061039 Ref: [Analysis of the protein expression and gene amplification of HER2 in gastric cancer]. PMID: 24062004 Ref: The utility of immunohistochemistry for providing genetic information on tumors. PMID: 24065374 Ref: Mucins in Gastric Cancer - An Update. PMID: 24077811 Ref: HER2 therapies and gastric cancer: a step forward. PMID: 24115812 Ref: Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. PMID: 24127447 Ref: HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. PMID: 24146218 Ref: Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. PMID: 24151357 Ref: HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays. PMID: 24151362 Ref: Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. PMID: 24176949 Ref: Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. PMID: 24196786 Ref: The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. PMID: 24244023 Ref: HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PMID: 24244671 Ref: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. PMID: 24252402 Ref: HER2 status in advanced gastric carcinoma: A retrospective multicentric analysis from Sicily. PMID: 24260051 Ref: Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. PMID: 24263233 Ref: Signal transduction of Helicobacter pylori during interaction with host cell protein receptors of epithelial and immune cells. PMID: 24280762 Ref: A case report of trastuzumab dose in gastric cancer. PMID: 24294514 Ref: The progress of targeted therapy in advanced gastric cancer. PMID: 24330856 Ref: [Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection]. PMID: 24394060 Ref: [A case of HER2-positive advanced gastric cancer successfully treated with a combination of capecitabine, cisplatin, and trastuzumab as first-line chemotherapy]. PMID: 24394076 Ref: [A case of SPT therapy( S-1+CDDP+trastuzumab) was successful for HER2-positive gastric cancer accompanied by distant lymph node metastasis]. PMID: 24394077 Ref: Synchronous rectal and gastric cancer in a fighter pilot: aeromedical concerns. PMID: 24426647 Ref: Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? PMID: 24453810 Ref: Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran. PMID: 24505530 Ref: HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma. PMID: 24551813 Ref: Metachronous liver and bone metastasis from small early gastric carcinoma without lymph node involvement: A case report. PMID: 24649155 Ref: [HER2 gene amplification and overexpression in advanced gastric cancer]. PMID: 24718467 Ref: HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. PMID: 25806223 Ref: Molecular therapy for gastric cancer. PMID: 25841446 |
Ref: Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. PMID: 23430266 Ref: Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. PMID: 23455716 Ref: Effects of a human compact anti-ErbB2 antibody on gastric cancer. PMID: 23460348 Ref: HER2-positive gastric cancer. PMID: 23563986 Ref: HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas. PMID: 23702645 Ref: Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. PMID: 23852704 Ref: Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. PMID: 23873022 Ref: Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. PMID: 23948998 Ref: Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. PMID: 23955257 Ref: Optimal chemotherapy for advanced gastric cancer: is there a global consensus? PMID: 24048758 Ref: Clinical significance and positive correlation of FoxM1 and Her-2 expression in gastric cancer. PMID: 24101296 Ref: Biomarkers of drugs targeting HER-family signalling in cancer. PMID: 24105684 Ref: HER2 in resected gastric cancer: Is there prognostic value? PMID: 24122802 Ref: The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. PMID: 24154840 Ref: HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. PMID: 24155030 Ref: The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. PMID: 24158524 Ref: TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer. PMID: 24178904 Ref: HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer. PMID: 24185685 Ref: T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. PMID: 24197131 Ref: Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. PMID: 24202699 Ref: Association of HER1 amplification with poor prognosis in well differentiated gastric carcinomas. PMID: 24218028 Ref: Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer. PMID: 24218279 Ref: Association analysis of ERBB2 amplicon genetic polymorphisms and STARD3 expression with risk of gastric cancer in the Chinese population. PMID: 24291029 Ref: Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. PMID: 24300914 Ref: Consistent absence of HER2 expression, regardless of HER2 amplification status, in neuroendocrine carcinomas of the stomach. PMID: 24329753 Ref: High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. PMID: 24379144 Ref: Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. PMID: 24403478 Ref: Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. PMID: 24414131 Ref: Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. PMID: 24421342 Ref: Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. PMID: 24449506 Ref: FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. PMID: 24457912 Ref: HER2 expression and PI3K-Akt pathway alterations in gastric cancer. PMID: 24458107 Ref: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines. PMID: 24472145 Ref: Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). PMID: 24473399 Ref: Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. PMID: 24491355 Ref: The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. PMID: 24492292 Ref: Correlations of beta-catenin, Ki67 and Her-2/neu with gastric cancer. PMID: 24507671 Ref: HER2-positive gastric cancer with paraaortic nodal metastasis successfully resected after chemotherapy with trastuzumab: a case report. PMID: 24511024 Ref: HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. PMID: 24518603 Ref: Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastric epithelial cells with DNA damage. PMID: 24530706 Ref: Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents. PMID: 24533716 Ref: Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. PMID: 24557541 Ref: [Risk factors and prognosis of liver metastasis from gastric cancer]. PMID: 24577761 Ref: A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. PMID: 24612546 Ref: HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio? PMID: 24614718 Ref: Prognostic implication of TSC1 and mTOR expression in gastric carcinoma. PMID: 24615476 Ref: Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. PMID: 24615495 Ref: Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway. PMID: 24623015 Ref: Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program. PMID: 24633707 Ref: Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). PMID: 24649329 Ref: HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer. PMID: 24656091 Ref: Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status. PMID: 24656529 Ref: Comment on Gu et al. entitled "Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis". PMID: 24664586 Ref: Recent advances and future trends in the targeted therapy of metastatic gastric cancer. PMID: 24665840 Ref: Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. PMID: 24668364 Ref: Feasibility of intraperitoneal Trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer. PMID: 24668709 Ref: Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. PMID: 24668895 Ref: The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis. PMID: 24670359 Ref: [Dual-color silver-enhanced in-situ hybridization for determination of HER2 gene amplification in gastric carcinoma]. PMID: 24713241 Ref: Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. PMID: 24728052 Ref: [HER2 protein testing in gastric cancer: a retrospective analysis of 1 471 cases during two different periods in a single medical center]. PMID: 24742566 Ref: [A case of advanced gastric cancer in which the serum HER2-ECD level could be used as a biomarker]. PMID: 24743367 Ref: Prognostic impact of major receptor tyrosine kinase expression in gastric cancer. PMID: 24743909 Ref: Treatment options in patients with metastatic gastric cancer: current status and future perspectives. PMID: 24744580 Ref: An updated review of gastric cancer in the next-generation sequencing era: insights from bench to bedside and vice versa. PMID: 24744582 Ref: Innovative personalized medicine in gastric cancer: time to move forward. PMID: 24749947 Ref: Lapatinib. PMID: 24756789 Ref: ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. PMID: 24767857 Ref: Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. PMID: 24775712 Ref: Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. PMID: 24782605 Ref: Targeting receptor tyrosine kinases in gastric cancer. PMID: 24782606 Ref: The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. PMID: 24806575 Ref: HER2 directed therapy for gastric/esophageal cancers. PMID: 24811128 Ref: Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report. PMID: 24822142 Ref: Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. PMID: 24868024 Ref: Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. PMID: 24889042 Ref: The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing. PMID: 24906218 Ref: Update on treatment of gastric cancer. PMID: 24907022 Ref: miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression. PMID: 24926380 Ref: Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. PMID: 24935174 Ref: BRCAA1 antibody- and Her2 antibody-conjugated amphiphilic polymer engineered CdSe/ZnS quantum dots for targeted imaging of gastric cancer. PMID: 24940175 Ref: A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. PMID: 24943493 Ref: Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo. PMID: 24947902 Ref: Quality of life in the trastuzumab for gastric cancer trial. PMID: 24951609 Ref: Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. PMID: 24953238 Ref: Sudden hearing loss due to internal auditory canal metastasis of Her2-positive gastric cancer: A case report. PMID: 24959283 Ref: A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. PMID: 24960402 Ref: Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. PMID: 24966791 Ref: Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. PMID: 24973425 Ref: Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review. PMID: 24982389 Ref: MicroRNA signature for HER2-positive breast and gastric cancer. PMID: 24982406 Ref: The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma. PMID: 25003395 Ref: Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. PMID: 25026283 Ref: Overexpression of miR-17 in gastric cancer is correlated with proliferation-associated oncogene amplification. PMID: 25047501 Ref: Significance of accurate human epidermal growth factor receptor-2 (HER2) evaluation as a new biomarker in gastric cancer. PMID: 25075048 Ref: Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. PMID: 25086186 Ref: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. PMID: 25107918 Ref: A germline mutation in the miR125a coding region reduces miR125a expression and is associated with human gastric cancer. PMID: 25109760 Ref: Lin28 promotes Her2 expression and Lin28/Her2 predicts poorer survival in gastric cancer. PMID: 25128063 Ref: How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. PMID: 25142842 Ref: Gastric carcinoma with an invasive micropapillary carcinoma component showing HER2 gene amplification and CD10 expression: a case report and review of the literature. PMID: 25143129 Ref: Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. PMID: 25189406 Ref: The role of HER3 in gastric cancer. PMID: 25194439 Ref: HER2-positive gastric cancer showing marked thickening of the gastric wall on ultrasonographic and computed tomographic scans. a chance phenomenon or a specific behaviour of this cancer type? Report of three cases. PMID: 25202095 Ref: Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma. PMID: 25209856 Ref: HER2/neu testing in primary colorectal carcinoma. PMID: 25211663 Ref: Human epidermal growth factor receptor 2 testing in gastric cancer: recommendations of an Asia-Pacific task force. PMID: 25227602 Ref: Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. PMID: 25232273 Ref: [A case of gastric cancer that responded to a preoperative combination therapy of S-1/CDDP plus trastuzumab]. PMID: 25248902 Ref: [A case of advanced gastric cancer with multiple liver, lung, and lymph node metastases treated with S-1, CDDP, and trastuzumab]. PMID: 25248905 Ref: Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry. PMID: 25289049 Ref: Evaluation of HER-2/neu overexpression in gastric carcinoma using a tissue microarray. PMID: 25292034 Ref: Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma. PMID: 25297519 Ref: Biosimilars lining up to compete with Herceptin--opportunity knocks. PMID: 25307085 Ref: Medical management of gastric cancer: a 2014 update. PMID: 25320502 Ref: Molecular targeting to treat gastric cancer. PMID: 25320512 Ref: IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status. PMID: 25323937 Ref: Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. PMID: 25327561 Ref: [Delay in formalin fixation and HER2 testing in gastric cancer]. PMID: 25327797 Ref: Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection. PMID: 25328763 Ref: [A case of unresectable Stage IV HER2-positive advanced gastric cancer treated by using trastuzumab combined with chemotherapy]. PMID: 25335729 Ref: HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. PMID: 25357111 Ref: High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PMID: 25372287 Ref: Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. PMID: 25374186 Ref: A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers. PMID: 25377592 Ref: Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. PMID: 25380654 Ref: Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model. PMID: 25401794 Ref: [Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report]. PMID: 25434447 Ref: Immunohistochemical HER2 expression not associated with clinicopathological characteristics of stage I-III gastric cancer patients. PMID: 25436385 Ref: Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. PMID: 25455899 Ref: Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis. PMID: 25479078 Ref: Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases. PMID: 25526216 Ref: [Pertuzumab and solid tumors: perspectives]. PMID: 25532690 Ref: Indian Council of Medical Research consensus document for the management of gastric cancer. PMID: 25538398 Ref: Detection of kinase amplifications in gastric adenocarcinomas. PMID: 25558650 Ref: Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy? PMID: 25605147 Ref: [A case of gastric cancer with solitary metachronous adrenal metastasis]. PMID: 25731488 Ref: [A case report of neuroendocrine carcinoma of the stomach with liver metastases curatively resected after neoadjuvant chemotherapy]. PMID: 25731498 Ref: [A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery]. PMID: 25731501 Ref: [A case of curative surgery for HER2-positive gastric cancer after chemotherapy using paclitaxel combined with trastuzumab]. PMID: 25731503 Ref: [Two cases of Stage IV Gastric cancer responding to chemotherapy and leading to pathological complete response]. PMID: 25731505 Ref: [A case of advanced gastric cancer successfully treated with trastuzumab, capecitabine, and Cisplatin therapy followed by curative resection]. PMID: 25731506 Ref: [A case of advanced gastric cancer with portal vein thrombus leading to liver metastases]. PMID: 25731516 Ref: [A case of advanced HER2- positive gastric cancer with a partial response to molecular targeted chemotherapy (S-1+CDDP+Trastuzumab)]. PMID: 25731518 Ref: [A case of locoregional recurrence after gastric cancer surgery, which was treated with XPT regimen chemotherapy]. PMID: 25731548 Ref: [Comparative study of the determination of the HER2 status in gastric cancer in the biopsy and intraoperative specimens]. PMID: 25842922 Ref: Advanced gastric cancer with liver and lymph node metastases successfully resected after induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil. PMID: 25872022 Ref: Is Helicobacter Pylori associated with Her2/neu Overexpression in Gastric Cancer Patients who Underwent Curative Resection? PMID: 26176087 Ref: Intrapleural Trastuzumab Therapy for Malignant Pleural Effusion from HER2 Overexpression in Metastatic Gastric Cancer. PMID: 26279275 Ref: Gastric Cancer: New Drugs - New Strategies. PMID: 26674336 Ref: (18)F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value. PMID: 27408854 |
Ref: Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. PMID: 24510342 Ref: Evaluation of serum HER2-ECD levels in patients with gastric cancer. PMID: 24557054 Ref: Micropapillary component in gastric adenocarcinoma: an aggressive variant associated with poor prognosis. PMID: 24562421 Ref: Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. PMID: 24626858 Ref: Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. PMID: 24662817 Ref: A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity. PMID: 24917219 Ref: HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). PMID: 24993498 Ref: HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. PMID: 25038874 Ref: MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. PMID: 25043310 Ref: HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. PMID: 25157953 Ref: The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. PMID: 25159729 Ref: Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. PMID: 25173363 Ref: HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis. PMID: 25176587 Ref: The HER2 gene and HER2 protein status and chromosome 17 polysomy in gastric cancer cells in own material. PMID: 25203430 Ref: Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. PMID: 25224659 Ref: College of American Pathologists Guidelines for Reporting HER2 Test Results in Gastric Cancer. PMID: 25295581 Ref: PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. PMID: 25300346 Ref: Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. PMID: 25306393 Ref: HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. PMID: 25322965 Ref: HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category? PMID: 25356940 Ref: HER2 testing in malignant effusions of metastatic gastric carcinoma: is it feasible? PMID: 25363414 Ref: Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients. PMID: 25378649 Ref: Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. PMID: 25391547 Ref: Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer. PMID: 25400108 Ref: Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. PMID: 25402270 Ref: Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas. PMID: 25402957 Ref: Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells. PMID: 25444894 Ref: The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. PMID: 25445175 Ref: Loss of heterozygosity of PTEN (encoding phosphate and tensin homolog) associated with elevated HER2 expression is an adverse prognostic indicator in gastric cancer. PMID: 25472613 Ref: TFF3 and HER2 expression and their correlation with survival in gastric cancer. PMID: 25514872 Ref: Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule. PMID: 25515030 Ref: Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. PMID: 25565860 Ref: HER2 assessment by silver in situ hybridization: where are we now? PMID: 25578771 Ref: Recent advances in the HER2 targeted therapy of gastric cancer. PMID: 25610849 Ref: HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria. PMID: 25611242 Ref: Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. PMID: 25624920 Ref: MMP-9 is increased in the pathogenesis of gastric cancer by the mediation of HER2. PMID: 25633484 Ref: Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. PMID: 25649416 Ref: Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. PMID: 25661103 Ref: Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer. PMID: 25684180 Ref: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. PMID: 25702260 Ref: The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. PMID: 25707491 Ref: HER2 expression status in diverse cancers: review of results from 37,992 patients. PMID: 25712293 Ref: Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. PMID: 25712681 Ref: Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. PMID: 25731189 Ref: Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites. PMID: 25732909 Ref: Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. PMID: 25743022 Ref: Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. PMID: 25744576 Ref: Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. PMID: 25749810 Ref: Clinicopathological significance of cytoplasmic transducer of ErbB2. 1 expression in gastric cancer. PMID: 25760308 Ref: A fluorescence in situ hybridization (FISH) microfluidic platform for detection of HER2 amplification in cancer cells. PMID: 25770459 Ref: Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. PMID: 25778705 Ref: The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. PMID: 25786580 Ref: HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. PMID: 25800719 Ref: [A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy]. PMID: 25812508 Ref: The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. PMID: 25820598 Ref: Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. PMID: 25828363 Ref: HER2 expression in gastric and oesophageal cancer: a meta-analytic review. PMID: 25830034 Ref: [Chemotherapy and trastuzumab for HER2 positive gastric cancer]. PMID: 25831826 Ref: HER2 testing in gastric and gastroesophageal adenocarcinomas. PMID: 25844677 Ref: Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature. PMID: 25859432 Ref: Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. PMID: 25862912 Ref: Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. PMID: 25863425 Ref: C-erbB-2 expression and prognosis of gastric cancer: a meta-analysis. PMID: 25867322 Ref: Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with "Polysomy 17". PMID: 25874002 Ref: Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy. PMID: 25879949 Ref: Role of c-mesenchymal-epithelial transition pathway in gastric cancer. PMID: 25881479 Ref: Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. PMID: 25882375 Ref: A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer. PMID: 25885256 Ref: Oncogenic HER2 fusions in gastric cancer. PMID: 25889497 Ref: Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? PMID: 25893119 Ref: Droplet digital PCR measurement of HER2 in patients with gastric cancer. PMID: 25897674 Ref: HER2 expression variability between primary gastric cancers and corresponding lymph node metastases. PMID: 25911901 Ref: Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma. PMID: 25914479 Ref: HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. PMID: 25937778 Ref: HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. PMID: 25954623 Ref: Magnetic resonance imaging of tumor with a self-traceable polymer conjugated with an antibody fragment. PMID: 25958246 Ref: Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. PMID: 26000013 Ref: alpha-Fetoprotein-Producing Hepatoid Gastric Adenocarcinoma With Osteoclast-Like Giant Cells and Neuroendocrine Differentiation: A Case Study With Molecular Profiling. PMID: 26009570 Ref: HER2/neu-directed therapy for biliary tract cancer. PMID: 26022204 Ref: Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. PMID: 26033320 Ref: Immunohistochemical expression of HER2 in adenocarcinoma of the stomach. PMID: 26039836 Ref: Molecular biomarkers in gastric cancer. PMID: 26052595 Ref: Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection. PMID: 26060493 Ref: A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? PMID: 26061272 Ref: Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer. PMID: 26077887 Ref: EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. PMID: 26081723 Ref: HER 2/neu protein expression in gastric cancer is associated with poor survival. PMID: 26096440 Ref: Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. PMID: 26099968 Ref: Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. PMID: 26099969 Ref: CORRELATION BETWEEN C-erbB-2 WITH GASTRIC MUCOSAL ATYPICAL HYPERPLASIA AND GASTRIC CARCINOMA. PMID: 26122239 Ref: Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. PMID: 26135662 Ref: Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. PMID: 26139980 Ref: [A Patient Who Underwent Surgery after CR to Chemotherapy for Scirrhous Gastric Cancer Suspected because of Lymphangitis Carcinomatosa]. PMID: 26199248 Ref: Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity. PMID: 26217940 Ref: Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil. PMID: 26225668 Ref: Affinity Maturation of Monoclonal Antibody 1E11 by Targeted Randomization in CDR3 Regions Optimizes Therapeutic Antibody Targeting of HER2-Positive Gastric Cancer. PMID: 26225765 Ref: Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives. PMID: 26254345 Ref: [Current standards in the treatment of gastric cancer]. PMID: 26261926 Ref: Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. PMID: 26287187 Ref: Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis. PMID: 26292093 Ref: A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients. PMID: 26313797 Ref: [Stage IV Gastric Cancer Made Resectable Following a Chemotherapy Regimen That Included Trastuzumab-A Case Report]. PMID: 26321717 Ref: A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JC PMID: 26355164 Ref: Advancing pharmacological treatment options for advanced gastric cancer. PMID: 26359224 Ref: Delineation of gastric cancer subtypes by co-regulated expression of receptor tyrosine kinases and chemosensitivity genes. PMID: 26396673 Ref: Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. PMID: 26401016 Ref: MiR-4728-3p could act as a marker of HER2 status. PMID: 26406406 Ref: Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues. PMID: 26435392 Ref: Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression. PMID: 26448177 Ref: Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. PMID: 26449765 Ref: Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. PMID: 26460823 Ref: Capecitabine for the treatment of gastric cancer. PMID: 26470733 Ref: Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. PMID: 26482716 Ref: [Clinicopathological Features and Outcomes of Treatment for HER2 Positive Gastric Cancer]. PMID: 26489575 Ref: [A Case of HER-2 Positive Advanced Gastric Cancer Responding to CapecitabineCisplatinTrastuzumab Chemotherapy]. PMID: 26489577 Ref: HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach. PMID: 26494937 Ref: Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. PMID: 26514182 Ref: Current and Future Therapies for Advanced Gastric Cancer. PMID: 26524924 Ref: Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. PMID: 26530403 Ref: [Development of a Dual Detection Method with Fluorescence In Situ Hybridization and Immunostaining on Formalin-Fixed Paraffin-Embedded Tissue Sections--Molecular Pathological Detection Techniques and Their Applications to Pathological Diagnosis]. PMID: 26548243 Ref: Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. PMID: 26560145 Ref: Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method. PMID: 26566289 Ref: Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis. PMID: 26587992 Ref: Gastric cancer: The times they are a-changin'. PMID: 26600930 Ref: A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients. PMID: 26622804 Ref: Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. PMID: 26623038 Ref: Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. PMID: 26625793 Ref: Seom guidelines for the treatment of gastric cancer 2015. PMID: 26691658 Ref: HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India. PMID: 26730043 Ref: Metastatic gastric carcinoma from breast cancer mimicking primary linitis plastica: A case report. PMID: 26788154 Ref: [Hepatic Resection of Multiple Liver Metastases from Gastric Cancer after Molecular Targeted Chemotherapy(S-1 plus Cisplatin plus Trastuzumab)]. PMID: 26805121 Ref: [Curative Surgery for Advanced Gastric Cancer with Extensive Lymph Node Metastasis after Long-Term Chemotherapy]. PMID: 26805132 Ref: [A Case of Granulocyte-Colony Stimulating Factor-Producing Gastric Cancer Successfully Treated with Trastuzumab]. PMID: 26805233 Ref: [A Case of a Submucosal Tumor-Like Gastric Cancer That Needed to Be Distinguished from Gastric Metastasis of Rectal Cancer]. PMID: 26805234 Ref: [A Case of Advanced Gastric Cancer with Synchronous Liver Metastases Treated with Combination Therapy]. PMID: 26805240 Ref: [A Case of HER2-Positive Advanced Gastric Cancer with a Pathological Complete Response to Neoadjuvant Chemotherapy with S-1/CDDP/Trastuzumab]. PMID: 26805258 Ref: [A Case of Unresectable Local Recurrence of Gastric Cancer Successfully Resected after Pre-Operative Chemotherapy with Trastuzumab]. PMID: 26805275 Ref: [HER2-Positive Advanced Gastric Cancer with Disseminated Intravascular Coagulation and Diffuse Bone Marrow Carcinomatosis Successfully Treated with S-1/Trastuzumab Chemotherapy--A Case Report]. PMID: 26809307 Ref: Breast and gastrointestinal cancer updates from ASCO 2015. PMID: 26855529 Ref: Perioperative and Palliative Chemotherapy for Esophageal Cancer. PMID: 26989390 Ref: Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. PMID: 28787954 |
Ref: HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. PMID: 25512144 Ref: A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility. PMID: 25640751 Ref: Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. PMID: 25682441 Ref: Detection and cultivation of circulating tumor cells in gastric cancer. PMID: 25862542 Ref: Gastric Carcinoma at the Era of Targeted Therapies. PMID: 25944013 Ref: Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. PMID: 25987463 Ref: Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications. PMID: 26002144 Ref: Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. PMID: 26016514 Ref: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). PMID: 26265390 Ref: HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases. PMID: 26317310 Ref: A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. PMID: 26323641 Ref: Evaluation of HER2 by automated FISH and IHC in gastric carcinoma biopsies. PMID: 26349667 Ref: Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. PMID: 26349670 Ref: Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. PMID: 26489445 Ref: Targeting HER 2 and angiogenesis in gastric cancer. PMID: 26567753 Ref: Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. PMID: 26581547 Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). PMID: 26621522 Ref: Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. PMID: 26626802 Ref: Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. PMID: 26643663 Ref: Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells. PMID: 26676300 Ref: A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas. PMID: 26685087 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). PMID: 26693898 Ref: Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials. PMID: 26697987 Ref: Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer. PMID: 26716644 Ref: Targeted therapy for gastric cancer: Current status and future directions (Review). PMID: 26718131 Ref: Substitution of Heavy Complementarity Determining Region 3 (CDR-H3) Residues Can Synergistically Enhance Functional Activity of Antibody and Its Binding Affinity to HER2 Antigen. PMID: 26743905 Ref: Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. PMID: 26752196 Ref: Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK). PMID: 26757197 Ref: Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer. PMID: 26759238 Ref: Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. PMID: 26797419 Ref: Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. PMID: 26810644 Ref: Targeted therapies in gastric cancer and future perspectives. PMID: 26811601 Ref: Personalized medicine in gastric cancer: Where are we and where are we going? PMID: 26811654 Ref: New guidelines for HER2 pathological diagnostics in gastric cancer. PMID: 26814046 Ref: Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer. PMID: 26832799 Ref: Current advances in targeted therapies for metastatic gastric cancer: improving patient care. PMID: 26838766 Ref: Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. PMID: 26846307 Ref: Effect of EGFR and p-AKT Overexpression on Chromosomal Instability in Gastric Cancer. PMID: 26847684 Ref: Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer. PMID: 26857264 Ref: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. PMID: 26857702 Ref: Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. PMID: 26874901 Ref: Advances of Molecular Targeted Therapy in Gastric Cancer. PMID: 26875080 Ref: Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. PMID: 26880697 Ref: Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. PMID: 26880889 Ref: Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer? PMID: 26891910 Ref: Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. PMID: 26893657 Ref: Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy. PMID: 26894650 Ref: Reply to the letter by Takeshi Yamada et al. concerning "Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?". PMID: 26897738 Ref: Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. PMID: 26919099 Ref: Clinical impact of tumour biology in the management of gastroesophageal cancer. PMID: 26925958 Ref: Advanced gastric cancer: Current treatment landscape and future perspectives. PMID: 26937129 Ref: APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis. PMID: 26942872 Ref: Translating gastric cancer genomics into targeted therapies. PMID: 26947813 Ref: Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. PMID: 26955870 Ref: Erratum to: Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy. PMID: 26956873 Ref: Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. PMID: 26966162 Ref: Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. PMID: 26970343 Ref: Monoclonal antibodies for treating gastric cancer: promises and pitfalls. PMID: 26971395 Ref: A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer. PMID: 27002325 Ref: Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. PMID: 27012666 Ref: Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. PMID: 27013889 Ref: Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. PMID: 27014419 Ref: DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. PMID: 27026201 Ref: Associations between serum CA724 and HER2 overexpression among stage II-III resectable gastric cancer patients: an observational study. PMID: 27027339 Ref: Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells. PMID: 27048593 Ref: HER2 Expression in Gastric Adenocarcinoma-a Study in a Tertiary Care Centre in South India. PMID: 27065677 Ref: [Molecular Subtypes of Gastric Cancer]. PMID: 27067842 Ref: HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. PMID: 27069134 Ref: Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening. PMID: 27076751 Ref: Insights into next developments in advanced gastric cancer. PMID: 27092990 Ref: A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth. PMID: 27107424 Ref: Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. PMID: 27119558 Ref: HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report. PMID: 27123269 Ref: Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. PMID: 27140836 Ref: Recent insights in the therapeutic management of patients with gastric cancer. PMID: 27156069 Ref: Gastric cancer. PMID: 27156933 Ref: JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients. PMID: 27167206 Ref: Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis. PMID: 27172248 Ref: The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas. PMID: 27175599 Ref: Evodiamine sensitizes BGC-823 gastric cancer cells to radiotherapy in vitro and in vivo. PMID: 27176933 Ref: A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. PMID: 27179810 Ref: Stromal-Based Signatures for the Classification of Gastric Cancer. PMID: 27197264 Ref: Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer. PMID: 27203688 Ref: [Complete Response in a Patient with HER2-Positive Gastric Cancer and Multiple Lung Metastases with Trastuzumab-Containing Chemotherapy]. PMID: 27210096 Ref: The role of targeted agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. PMID: 27212163 Ref: Personalised Treatment in Gastric Cancer: Myth or Reality? PMID: 27215435 Ref: HER2 testing in gastric cancer: An update. PMID: 27217694 Ref: Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. PMID: 27256004 Ref: Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. PMID: 27257141 Ref: Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy. PMID: 27259008 Ref: An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. PMID: 27267856 Ref: Profile of HER2 +ve Gastric Cancers in Brunei Darussalam. PMID: 27268629 Ref: [Correlation between cyclin-dependent kinase inhibitor p27kip1 and trastuzumab-resistance in gastric cancer]. PMID: 27269920 Ref: HER2-positive gastric cancer identified by serum HER2: A case report. PMID: 27284358 Ref: [A Case of HER2-Positive Esophagogastric Junction Cancer with Perforation Curatively Resected after Neoadjuvant Chemotherapy plus Trastuzumab]. PMID: 27306816 Ref: The predictors of response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. PMID: 27314292 Ref: A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer. PMID: 27325685 Ref: Bifunctional alphaHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. PMID: 27339087 Ref: Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China. PMID: 27340357 Ref: A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth. PMID: 27363335 Ref: Prognostic values of four Notch receptor mRNA expression in gastric cancer. PMID: 27363496 Ref: [HER2 testing in gastric cancer : Results of a meeting of German experts]. PMID: 27376648 Ref: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. PMID: 27384994 Ref: A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors. PMID: 27387446 Ref: Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. PMID: 27409420 Ref: Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. PMID: 27437872 Ref: HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. PMID: 27468182 Ref: Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells. PMID: 27473824 Ref: Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2- Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG). PMID: 27486629 Ref: [Guidelines for HER2 detection in gastric cancer(2016)]. PMID: 27510777 Ref: Gastric biomarkers: a global review. PMID: 27514667 Ref: Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment. PMID: 27517841 Ref: HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis. PMID: 27536774 Ref: HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. PMID: 27578417 Ref: A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway. PMID: 27581375 Ref: Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. PMID: 27623234 Ref: [A Case of HER2-Positive Stage IV Advanced Gastric Cancer Treated with Chemotherapy Combined with Trastuzumab]. PMID: 27628555 Ref: Paraneoplastic Limbic Encephalitis in a Human Epidermal Growth Factor Receptor-2-positive Gastric Cancer Patient Treated with Trastuzumab-combined Chemotherapy: A Case Report and Literature Review. PMID: 27629954 Ref: HER2-targeted recombinant protein immuno-caspase-6 effectively induces apoptosis in HER2-overexpressing GBM cells in vitro and in vivo. PMID: 27633091 Ref: An update in the nonendoscopic treatment of gastric cancer. PMID: 27636304 Ref: Management of advanced gastric cancer: An overview of major findings from meta-analysis. PMID: 27655725 Ref: 3D pharmacophore-based virtual screening, docking and density functional theory approach towards the discovery of novel human epidermal growth factor receptor-2 (HER2) inhibitors. PMID: 27693363 Ref: Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. PMID: 27697982 Ref: Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer. PMID: 27697983 Ref: JWA down-regulates HER2 expression via c-Cbl and induces lapatinib resistance in human gastric cancer cells. PMID: 27708243 Ref: Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer. PMID: 27714846 Ref: The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study. PMID: 27729801 Ref: Involvement of microRNAs in HER2 signaling and trastuzumab treatment. PMID: 27734339 Ref: The prospect of patritumab for treating non-small cell lung cancer. PMID: 27744717 Ref: The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. PMID: 27747089 Ref: Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis. PMID: 27752391 Ref: [Remarkable Response to Trastuzumab Observed in a Case of Gastric Cancer with HER2-Negative Conversion]. PMID: 27760939 Ref: [A Case of HER2-Positive Advanced Gastric Cancer with Multiple Liver Metastases Effectively Treated with Trastuzumab, Capecitabine, and Cisplatin Combination Therapy]. PMID: 27760940 Ref: Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. PMID: 27765925 Ref: Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. PMID: 27766079 Ref: Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. PMID: 27768588 Ref: Increased expression of EHF via gene amplification contributes to the activation of HER family signaling and associates with poor survival in gastric cancer. PMID: 27787520 Ref: Targeted therapy in gastric cancer. PMID: 27795701 Ref: A case report of chylous ascites after gastric bypass for morbid obesity. PMID: 27846453 Ref: Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of Syzygium alternifolium through molecular dynamics and pharmacophore-based screening. PMID: 27853354 Ref: HER2-induced metastasis is mediated by AKT/JNK/EMT signaling pathway in gastric cancer. PMID: 27895401 Ref: Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. PMID: 28028387 Ref: Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers. PMID: 28078044 Ref: Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma. PMID: 28105465 Ref: [A Case of Port Site Recurrence after Laparoscopic Distal Gastrectomy for Advanced Gastric Cancer]. PMID: 28133037 Ref: [A Case of Advanced Gastric Cancer with Extensive Lymph Node Metastases Treated by Capecitabine plus Cisplatin plus Trastuzumab Chemotherapy,Followed by Conversion Surgery]. PMID: 28133177 Ref: [A Patient with HER2-Positive Stage IV Advanced Gastric Cancer Who Received Chemotherapy with Trastuzumab plus XP Followed by Conversion Surgery]. PMID: 28133183 Ref: [A Case of Advanced Gastric Cancer Successfully Treated with Curative Conversion Surgery after Chemotherapy with S-1 plus Oxaliplatin]. PMID: 28133273 Ref: A morphological and immunohistochemical evaluation of gastric carcinoma in the Western Cape province of South Africa. PMID: 28240491 Ref: Prospective evaluation of changes in tumor size and tumor metabolism in advanced gastric cancer undergoing chemotherapy: association and clinical implication PMID: 28271703 Ref: Human epidermal growth factor receptor 2 expression in gastric carcinoma and its association with histopathological parameters in Indian population. PMID: 28485339 |
Ref: Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis. PMID: 26549693 Ref: Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. PMID: 26874951 Ref: Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis. PMID: 27324991 Ref: HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease. PMID: 27363700 Ref: Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). PMID: 27521503 Ref: Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. PMID: 27599830 Ref: Plasma levels of trastuzumab in gastric cancer: Case report. PMID: 27664112 Ref: Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. PMID: 27687309 Ref: Global chemotherapy development for gastric cancer. PMID: 27718136 Ref: Distinct expression profile of key molecules in crawling-type early gastric carcinoma. PMID: 27734272 Ref: Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. PMID: 27864121 Ref: Detection of Her2-overexpressing cancer cells using keyhole shaped chamber array employing a magnetic droplet-handling system. PMID: 27866824 Ref: Cholesterol import and steroidogenesis are biosignatures for gastric cancer patient survival. PMID: 27893427 Ref: Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. PMID: 27933395 Ref: LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer. PMID: 27942917 Ref: Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. PMID: 27976952 Ref: HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? PMID: 27981460 Ref: Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study. PMID: 28008715 Ref: Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. PMID: 28027945 Ref: Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer. PMID: 28039034 Ref: MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma. PMID: 28052014 Ref: [Immunohistochemical assessment of HER2 expression in gastric cancer. A clinicopathologic study of 93 cases]. PMID: 28069112 Ref: miR 1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression. PMID: 28099468 Ref: MicroRNA-133a Inhibits Proliferation of Gastric Cancer Cells by Downregulating ERBB2 Expression. PMID: 28109082 Ref: Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips. PMID: 28111342 Ref: First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. PMID: 28119295 Ref: Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. PMID: 28160563 Ref: [A Case of Synchronous Double Cancer of the Lung and Stomach That Responded to Cisplatin and S-1 Combination Chemotherapy]. PMID: 28174383 Ref: New agents on the horizon in gastric cancer. PMID: 28184417 Ref: Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. PMID: 28205537 Ref: [Novel pharmaceutical treatment approaches for gastric cancer]. PMID: 28220199 Ref: Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition. PMID: 28223426 Ref: Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas. PMID: 28224267 Ref: Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line. PMID: 28260018 Ref: Immunohistochemical analysis of PTEN, HER2/neu, and ki67 expression in patients with gastric cancer and their association with survival. PMID: 28262306 Ref: Predictive biomarkers along gastric cancer pathogenetic pathways. PMID: 28277834 Ref: HER2 testing in gastric cancer: results of a German expert meeting. PMID: 28285403 Ref: Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. PMID: 28292264 Ref: The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. PMID: 28327158 Ref: Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall? PMID: 28327938 Ref: Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro-Esophageal Junction Cancer. PMID: 28337363 Ref: Reduction of miR1323p contributes to gastric cancer proliferation by targeting MUC13. PMID: 28339011 Ref: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. PMID: 28343975 Ref: Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer. PMID: 28348489 Ref: About HER2 monitoring using liquid biopsies in patients with gastric cancer. PMID: 28357608 Ref: HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. PMID: 28363756 Ref: [Clinical significance of HER2 positivity in gallbladder adenocarcinoma]. PMID: 28376590 Ref: Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. PMID: 28388007 Ref: Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. PMID: 28388541 Ref: Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer. PMID: 28399526 Ref: Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer. PMID: 28404903 Ref: Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. PMID: 28405494 Ref: The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. PMID: 28415835 Ref: High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival. PMID: 28465671 Ref: Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis. PMID: 28477027 Ref: Management of Metastatic Gastric Cancer. PMID: 28501088 Ref: Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance. PMID: 28507275 Ref: Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. PMID: 28508152 Ref: HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks. PMID: 28513868 Ref: Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers. PMID: 28514733 Ref: Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody. PMID: 28514745 Ref: Molecular classifications of gastric cancers: Novel insights and possible future applications. PMID: 28567184 Ref: Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. PMID: 28572288 Ref: Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. PMID: 28584793 Ref: HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. PMID: 28588175 Ref: Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. PMID: 28612195 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization. PMID: 28639750 Ref: Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer. PMID: 28640116 Ref: Influence of Anthropometric Characteristics in Patients With Her2-Positive Breast Cancer on Initial Plasma Concentrations of Trastuzumab. PMID: 28643558 Ref: Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer. PMID: 28672982 Ref: DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. PMID: 28677116 Ref: [A Case of Long-Term Survival of a Patient with Gastric Cancer with Synchronous Liver Metastasis and Portal Vein Thrombus after Multidisciplinary Treatment]. PMID: 28698446 Ref: Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling. PMID: 28713919 Ref: Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. PMID: 28736628 Ref: Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. PMID: 28736629 Ref: Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing. PMID: 28744403 Ref: Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry. PMID: 28765618 Ref: Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer. PMID: 28781693 Ref: [Good remission under HER2 blockade in an advanced carcinoma of the oesophagogastric junction with only focal HER2 overexpression]. PMID: 28787750 Ref: Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. PMID: 28801248 Ref: Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy. PMID: 28821938 Ref: HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. PMID: 28823752 Ref: The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2. PMID: 28868025 Ref: siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells. PMID: 28881753 Ref: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. PMID: 28899363 Ref: Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma. PMID: 28900323 Ref: Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples. PMID: 28901323 Ref: Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. PMID: 28910818 Ref: Multicenter phase II study of capecitabine plus cisplatin as first-line therapy for human epidermal growth factor receptor 2-negative advanced gastric cancer: Yokohama Clinical Oncology Group Study YCOG1107. PMID: 28913549 Ref: Targeted therapies for gastric cancer: failures and hopes from clinical trials. PMID: 28915702 Ref: Expression of pRb, Ki67 and HER 2/neu in gastric carcinomas: Relation to different histopathological grades and stages. PMID: 28965621 Ref: Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. PMID: 28977908 Ref: Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature. PMID: 29034239 Ref: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). PMID: 29043411 Ref: Association of sirtuins with clinicopathological parameters and overall survival in gastric cancer. PMID: 29088792 Ref: Actionable gene-based classification toward precision medicine in gastric cancer. PMID: 29089060 Ref: Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer. PMID: 29094049 Ref: Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis. PMID: 29095284 Ref: Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. PMID: 29143776 Ref: Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. PMID: 29151694 Ref: Establishment of H2Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer. PMID: 29172998 Ref: [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer]. PMID: 29178102 Ref: Functions of the AP-2alpha gene in activating apoptosis and inhibiting proliferation of gastric cancer cells both in vitro and in vivo. PMID: 29181055 Ref: Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. PMID: 29189161 Ref: Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer. PMID: 29190909 Ref: DNMT1 overexpression predicting gastric carcinogenesis, subsequent progression and prognosis: a meta and bioinformatic analysis. PMID: 29221215 Ref: Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients. PMID: 29233126 Ref: Strengthening Gastric Cancer Therapy by Trastuzumab-Conjugated Nanoparticles with Simultaneous Encapsulation of Anti-MiR-21 and 5-Fluorouridine. PMID: 29241186 Ref: Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. PMID: 29254172 Ref: Recurrence in node-negative advanced gastric cancer: Novel findings from an in-depth pathological analysis of prognostic factors from a multicentric series. PMID: 29259375 Ref: Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. PMID: 29265917 Ref: Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype. PMID: 29295527 Ref: HER-2/neu gene amplification in gastric adenocarcinoma and its relationship with clinical and pathological findings. PMID: 29299365 Ref: Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing. PMID: 29307989 Ref: First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis f PMID: 29340092 Ref: Immunohistochemical expression of CDX2, CK7, HER2 and HER4 in periampullary adenocarcinoma : implications for clinicopathology and patient outcomes. PMID: 29364095 Ref: PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. PMID: 29371924 Ref: [A Case of Advanced Gastric Cancer with Synchronous Liver Metastases Responding to Preoperative Combination Chemotherapy with S-1 plus Oxaliplatin(SOX)]. PMID: 29394601 Ref: [A Case of HER2-Positive Unresectable Gastric Cancer with Multiple Lymph Node and Liver Metastases Controlled Effectively by Combination Chemotherapy with Capecitabine, Oxaliplatin, and Trastuzumab]. PMID: 29394602 Ref: [The Case of HER2 Positive Advanced Gastric Cancer with Para-Aorta Lymph Node Recurrence Responding to Capecitabine plus CDDP plus Trastuzumab Chemotherapy]. PMID: 29394666 Ref: [A Case Report of Gastric Cancer with Positive Peritoneal Lavage Cytology and Metachronous Schnitzler's Metastasis Treated with Multimodality Therapy]. PMID: 29394723 Ref: [Two Cases of HER2-Positive Gastric Cancer with Multiple Liver Metastases Leading to Conversion Therapy with Chemotherapy]. PMID: 29394735 Ref: [A Case of Synchronous Quadruple Cancers Treated with Neoadjuvant Chemotherapy Followed by Surgery]. PMID: 29394804 |
Ref: HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. PMID: 27490762 Ref: Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. PMID: 27975180 Ref: Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia. PMID: 28124769 Ref: Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. PMID: 28284008 Ref: FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation. PMID: 28343375 Ref: Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). PMID: 28497176 Ref: Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer. PMID: 28584889 Ref: The prognostic value of volume-based parameters using (18)F-FDG PET/CT in gastric cancer according to HER2 status. PMID: 28643145 Ref: An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis. PMID: 28681313 Ref: Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma. PMID: 28753766 Ref: Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. PMID: 28859471 Ref: Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2. PMID: 29036807 Ref: Gastric cancer: immunohistochemical classification of molecular subtypes and their association with clinicopathological characteristics. PMID: 29046940 Ref: Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. PMID: 29090377 Ref: The Epithelial-Mesenchymal Transition Pathway in Two Cases with Gastric Metastasis Originating from Breast Carcinoma, One with a Metachronous Primary Gastric Cancer. PMID: 29090670 Ref: CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. PMID: 29106389 Ref: Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer. PMID: 29125480 Ref: Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. PMID: 29138285 Ref: Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study. PMID: 29168107 Ref: HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. PMID: 29169184 Ref: Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. PMID: 29174919 Ref: Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC). PMID: 29189914 Ref: H19 functions as a competing endogenous RNA to regulate human epidermal growth factor receptor expression by sequestering let7c in gastric cancer. PMID: 29207111 Ref: HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. PMID: 29207318 Ref: NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer. PMID: 29231994 Ref: Correction to: Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC06). PMID: 29234896 Ref: Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer. PMID: 29271513 Ref: Establishment of a Patient-derived Xenograft for Development of Personalized HER2-targeting Therapy in Gastric Cancer. PMID: 29277785 Ref: Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. PMID: 29277796 Ref: EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. PMID: 29278885 Ref: A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). PMID: 29290024 Ref: miR-200c inhibits TGF-beta-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer. PMID: 29302045 Ref: HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. PMID: 29305518 Ref: Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy. PMID: 29310611 Ref: Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer. PMID: 29315012 Ref: Correlation of Gli1 and HER2 expression in gastric cancer: Identification of novel target. PMID: 29321573 Ref: Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. PMID: 29325228 Ref: Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. PMID: 29328489 Ref: Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer. PMID: 29344282 Ref: Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway. PMID: 29393362 Ref: Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. PMID: 29409051 Ref: The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. PMID: 29416757 Ref: Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. PMID: 29416924 Ref: Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. PMID: 29433585 Ref: Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. PMID: 29434871 Ref: Morphologic and Immunohistochemical Appraisal of Primary Gastric Carcinomas. PMID: 29438113 Ref: Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features. PMID: 29438172 Ref: MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding In Vivo Activity against HER2-Expressing Tumors. PMID: 29440297 Ref: Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. PMID: 29451302 Ref: Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter. PMID: 29462252 Ref: Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. PMID: 29463236 Ref: Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. PMID: 29465762 Ref: Efficacy and safety of the trastuzumab biosimilar candidate CT-P6. PMID: 29482364 Ref: [Indication of Palliative Gastrojejunostomy for Unresectable Advanced Gastric Cancer with Obstruction from the View Point of Preoperative Inflammatory Biomarkers]. PMID: 29483439 Ref: A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. PMID: 29488122 Ref: [Surgical treatment and prognosis of Borrmann type IIII( gastric cancer involving the whole stomach]. PMID: 29492918 Ref: Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. PMID: 29500656 Ref: Prognostic implications of HER2 heterogeneity in gastric cancer. PMID: 29507688 Ref: Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis. PMID: 29512712 Ref: Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. PMID: 29515767 Ref: Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets. PMID: 29522457 Ref: Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. PMID: 29530054 Ref: The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. PMID: 29535422 Ref: Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab. PMID: 29541179 Ref: Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. PMID: 29544445 Ref: [Predictive diagnostics of gastric cancer in 2018]. PMID: 29631408 Ref: Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. PMID: 29633013 Ref: Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib. PMID: 29637613 Ref: Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. PMID: 29659677 Ref: Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. PMID: 29673110 Ref: Significance of aquaporins' expression in the prognosis of gastric cancer. PMID: 29678898 Ref: Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. PMID: 29685755 Ref: RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. PMID: 29686309 Ref: The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma. PMID: 29696715 Ref: Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma. PMID: 29697008 Ref: Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab. PMID: 29700210 Ref: Human gastric cancer modelling using organoids. PMID: 29703791 Ref: Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. PMID: 29714649 Ref: Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy. PMID: 29715156 Ref: Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. PMID: 29720111 Ref: Upregulation of bone morphogenetic protein 1 is associated with poor prognosis of late-stage gastric Cancer patients. PMID: 29720137 Ref: Human Epidermal Growth Factor Receptor-2 Promotes Invasion and Metastasis in Gastric Cancer by Activating Mitogen-activated Protein Kinase Signaling. PMID: 29734245 Ref: Distinct Expression and Prognostic Value of MS4A in Gastric Cancer. PMID: 29756054 Ref: miR494 inhibits cancerinitiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2positive gastric cancer. PMID: 29786108 Ref: A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. PMID: 29792724 Ref: Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India PMID: 29802704 Ref: Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. PMID: 29806596 Ref: Paeonol induces the apoptosis of the SGC7901 gastric cancer cell line by downregulating ERBB2 and inhibiting the NFkappaB signaling pathway. PMID: 29845222 Ref: A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. PMID: 29845329 Ref: Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas. PMID: 29851704 Ref: HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer. PMID: 29885899 Ref: Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). PMID: 29886081 Ref: Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. PMID: 29921305 Ref: Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis. PMID: 29937450 Ref: HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran PMID: 29938472 Ref: Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. PMID: 29951752 Ref: Consequences of blunting the mevalonate pathway in cancer identified by a pluri-omics approach. PMID: 29970880 Ref: Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. PMID: 29978335 Ref: Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/beta-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer. PMID: 29986466 Ref: DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells. PMID: 29987267 Ref: Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. PMID: 29992451 Ref: Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features. PMID: 30006753 Ref: Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report. PMID: 30008904 Ref: Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. PMID: 30012565 Ref: Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. PMID: 30041572 Ref: HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics. PMID: 30087720 Ref: The molecular mechanism and clinical significance of LDHA in HER2-mediated progression of gastric cancer. PMID: 30093943 Ref: HER2: An emerging target in colorectal cancer. PMID: 30100092 Ref: Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). PMID: 30105460 Ref: Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naive Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial. PMID: 30115736 Ref: FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. PMID: 30120163 Ref: Association of HER2 gene amplification and tumor progression in early gastric cancer. PMID: 30120594 Ref: Cross-Database Analysis Reveals Sensitive Biomarkers for Combined Therapy for ERBB2+ Gastric Cancer. PMID: 30123134 Ref: Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. PMID: 30124494 Ref: Berberine: A potential adjunct for the treatment of gastrointestinal cancers? PMID: 30125974 Ref: Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer. PMID: 30134903 Ref: MicroRNA-495 Confers Increased Sensitivity to Chemotherapeutic Agents in Gastric Cancer via the Mammalian Target of Rapamycin (mTOR) Signaling Pathway by Interacting with Human Epidermal Growth Factor Receptor 2 (ERBB2). PMID: 30147110 Ref: Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination. PMID: 30171392 Ref: Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model. PMID: 30214017 Ref: Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report. PMID: 30214596 Ref: Development of a novel anti-HER2 scFv by ribosome display and in silico evaluation of its 3D structure and interaction with HER2, alone and after fusion to LAMP2B. PMID: 30225583 Ref: Increasing HER2 alpha2,6 sialylation facilitates gastric cancer progression and resistance via the Akt and ERK pathways. PMID: 30226606 Ref: Clinicopathological significance of claspin overexpression and its association with spheroid formation in gastric cancer. PMID: 30240769 Ref: Non-invasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients. PMID: 30251865 Ref: Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer. PMID: 30275713 Ref: PF-05280014: A Trastuzumab Biosimilar. PMID: 30280367 Ref: Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis. PMID: 30310315 Ref: The safety of apatinib for the treatment of gastric cancer. PMID: 30324820 Ref: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. PMID: 30328533 Ref: Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer. PMID: 30348707 Ref: LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1. PMID: 30349368 Ref: Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer. PMID: 30350178 Ref: Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. PMID: 30365359 Ref: Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. PMID: 30379568 Ref: [A Case of Long-Term Survival with Multidisciplinary Treatment in Unresectable Advanced Gastric Cancer Found with Ovarian Tumor]. PMID: 30382054 Ref: Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). PMID: 30386954 |